<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134004</url>
  </required_header>
  <id_info>
    <org_study_id>J0457 CDR0000440990</org_study_id>
    <secondary_id>P01CA015396</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0457</secondary_id>
    <secondary_id>JHOC-04072704</secondary_id>
    <nct_id>NCT00134004</nct_id>
  </id_info>
  <brief_title>Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer</brief_title>
  <official_title>A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and&#xD;
      radiation therapy before a donor bone marrow transplant helps stop the growth of cancer&#xD;
      cells. Giving chemotherapy or radiation therapy before or after transplant also stops the&#xD;
      patient's immune system from rejecting the donor's bone marrow stem cells. The donated stem&#xD;
      cells may replace the patient's immune system cells and help destroy any remaining cancer&#xD;
      cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also&#xD;
      make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate&#xD;
      mofetil after the transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide&#xD;
      together with total-body irradiation works in treating patients who are undergoing a donor&#xD;
      bone marrow transplant for hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine transplant-related mortality, risk of relapse, and progression-free survival&#xD;
           of patients with standard- or high-risk hematologic malignancies undergoing&#xD;
           nonmyeloablative conditioning comprising fludarabine, cyclophosphamide, and total-body&#xD;
           irradiation followed by HLA-haploidentical allogeneic bone marrow transplantation.&#xD;
&#xD;
        -  Determine donor hematopoietic chimerism in patients' peripheral blood at 30, 60, and 180&#xD;
           days after transplantation.&#xD;
&#xD;
        -  Determine hematologic and nonhematologic toxic effects of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine, when feasible, surface expression of HLA molecules and death receptors,&#xD;
           sensitivity to cytotoxic lymphocytes, and expression of anti-apoptotic genes (e.g.,&#xD;
           Bcl-2, Bcl-xL, X-IAP, and c-FLIP) in cancer cells from patients who relapse after&#xD;
           treatment with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to risk of relapse&#xD;
      (standard [defined as ≤ 30% risk] vs high [defined as ≥ 70% risk]).&#xD;
&#xD;
        -  Nonmyeloablative conditioning regimen: Patients receive fludarabine IV over 30 minutes&#xD;
           on days -6 to -2 and cyclophosphamide IV over 1-2 hours on days -6 and -5. Patients&#xD;
           undergo total body irradiation on day -1.&#xD;
&#xD;
        -  Allogeneic bone marrow transplantation: Patients undergo donor bone marrow infusion on&#xD;
           day 0.&#xD;
&#xD;
        -  Post-transplantation therapy: Patients receive cyclophosphamide IV over 1-2 hours on&#xD;
           days 3 and 4.&#xD;
&#xD;
        -  Graft-vs-host disease prophylaxis: Beginning on day 5, patients receive oral&#xD;
           mycophenolate mofetil 3 times daily until day 35 and tacrolimus IV (then changing to&#xD;
           orally) twice daily until day 180.&#xD;
&#xD;
      Treatment continues in the absence of disease progression.&#xD;
&#xD;
      After completion of study transplantation, patients are followed on days 30, 60, 100, and&#xD;
      180; at 1 year; and then annually for 4 additional years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 75-100 patients will be accrued for this study within 3-4&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant-related Mortality</measure>
    <time_frame>Cumulative incidence for the entire study, up to 11 years</time_frame>
    <description>Percentage of participants who die for any reason other than recurrence of disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>Cumulative incidence for the entire study, up to 11 years</time_frame>
    <description>Percentage of participants who experience disease relapse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of participants who do not experience disease relapse, disease progression, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft Failure Rate</measure>
    <time_frame>Cumulative incidence for the entire study, up to 11 years</time_frame>
    <description>Percentage of participants who experienced failure to engraft (also called graft failure or graft rejection). Failure to engraft is defined as &lt;5% donor chimerism and absence of relapse or any other reason for that chimerism value. All participants who met this criterion were included in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic and Non-hematologic Toxicities as Measured by NCI Common Toxicity Criteria for Adverse Events, v 3.0 Weekly Until 1 Year After Transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of study participants who experienced a serious adverse event (SAE) within 1 year of bone marrow transplant. Complete data is provided in the Adverse Event tables.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Mini-haplo Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Mini-haplo Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>Mini-haplo Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <arm_group_label>Mini-haplo Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>Mini-haplo Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <arm_group_label>Mini-haplo Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Mini-haplo Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following hematologic malignancies:&#xD;
&#xD;
               -  Acute leukemia&#xD;
&#xD;
                    -  In second or subsequent complete remission (CR), as defined by absence of&#xD;
                       abnormal blast population by flow cytometry&#xD;
&#xD;
                    -  In first CR with any of the following poor-risk cytogenetic features:&#xD;
&#xD;
                         -  Alteration of chromosome 5 or 7&#xD;
&#xD;
                         -  Multiple abnormalities&#xD;
&#xD;
                         -  Philadelphia chromosome positive&#xD;
&#xD;
               -  Chronic phase chronic myelogenous leukemia (CML)&#xD;
&#xD;
                    -  In first chronic phase and refractory to interferon alfa or imatinib&#xD;
                       mesylate&#xD;
&#xD;
                    -  In second or subsequent chronic phase&#xD;
&#xD;
               -  Chronic lymphocytic leukemia, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Received prior chemotherapy with a nucleoside analog and had remission&#xD;
                       lasting &lt; 6 months&#xD;
&#xD;
                    -  Received 1 prior therapy and has any of the following high-risk features:&#xD;
&#xD;
                         -  Cytogenetic abnormalities of 17p, 11q&#xD;
&#xD;
                         -  Mutations of the Zap70 gene&#xD;
&#xD;
                         -  Somatically unmutated immunoglobulin heavy chain variable region genes&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
                    -  Ineligible for autologous stem cell transplantation (SCT) due to any of the&#xD;
                       following exclusion factors:&#xD;
&#xD;
                         -  LVEF &lt; 45%&#xD;
&#xD;
                         -  FEV_1 or FVC &lt; 50% of predicted (75% of predicted in patients with&#xD;
                            prior thoracic or mantle radiotherapy)&#xD;
&#xD;
                         -  Total bilirubin &gt; 2.0 mg/dL (unless documented Gilbert's disease)&#xD;
&#xD;
                         -  Creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
                    -  Low-grade NHL allowed provided patient had a remission duration of &lt; 1 year&#xD;
                       after administration of any established, multi-agent chemotherapy regimen&#xD;
                       (e.g., CVP, CHOP, or rituximab in combination with CHOP)&#xD;
&#xD;
                    -  Intermediate- or high-grade NHL allowed provided patient is ineligible for&#xD;
                       autologous SCT according to the criteria listed above&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  Myelodysplastic syndromes&#xD;
&#xD;
               -  Paroxysmal nocturnal hemoglobinuria&#xD;
&#xD;
               -  Chronic myeloproliferative disorders other than CML, including any of the&#xD;
                  following:&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
                    -  Agnogenic myeloid metaplasia (or myeloid metaplasia with myelofibrosis),&#xD;
                       with hemoglobin &lt; 10 g/dL OR WBC &lt; 4,000/mm^3 or &gt; 30,000/mm^3&#xD;
&#xD;
                    -  Polycythemia vera or essential thrombocythemia in &quot;spent&quot; phase, with a&#xD;
                       history of 2 of the following:&#xD;
&#xD;
                         -  Marrow fibrosis&#xD;
&#xD;
                         -  Splenomegaly&#xD;
&#xD;
                         -  Cytopenia (i.e., absolute neutrophil count &lt; 1,500/mm^3, platelet count&#xD;
                            &lt; 100,000/mm^3, hemoglobin &lt; 10 g/dL)&#xD;
&#xD;
                    -  Polycythemia vera or essential thrombocythemia with transformation to&#xD;
                       myelodysplastic syndromes or acute myeloid leukemia (requires treatment to&#xD;
                       achieve &lt; 20% blasts in marrow)&#xD;
&#xD;
          -  No smoldering myeloma&#xD;
&#xD;
          -  Patients with acute myeloid leukemia or myelodysplastic syndromes must have had&#xD;
             comprehensive cytogenetic evaluation of bone marrow specimen during active disease&#xD;
&#xD;
          -  Ineligible for or refused bone marrow transplantation from an HLA-matched sibling or&#xD;
             unrelated donor&#xD;
&#xD;
          -  Ineligible for or refused autologous SCT&#xD;
&#xD;
          -  Must have an HLA mismatched (i.e., 3/6, 4/6, or 5/6) related (first-degree relative)*&#xD;
             donor available&#xD;
&#xD;
               -  Donor ≥ 18 years of age NOTE: *Patients with an inherited recombinant HLA&#xD;
                  haplotype may receive marrow from the parent in whose gamete the recombination&#xD;
                  occurred&#xD;
&#xD;
        NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.&#xD;
        The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology&#xD;
        of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
        terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  6 months to 74 years&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin &lt; 3.1 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  LVEF ≥ 35%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  FEV_1 or FVC ≥ 40% of predicted in patients without prior thoracic or mantle&#xD;
             radiotherapy (60% of predicted in patients with prior thoracic or mantle radiotherapy)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Geographically accessible&#xD;
&#xD;
          -  No debilitating medical or psychiatric illness that would preclude giving informed&#xD;
             consent or receiving optimal treatment or follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior transfusions from donor&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ephraim J. Fuchs, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Program at Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102-1192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2005</study_first_posted>
  <results_first_submitted>June 26, 2015</results_first_submitted>
  <results_first_submitted_qc>July 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2015</results_first_posted>
  <last_update_submitted>September 2, 2015</last_update_submitted>
  <last_update_submitted_qc>September 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mini-haplo BMT</title>
          <description>Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mini-haplo BMT</title>
          <description>Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="1" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Transplant-related Mortality</title>
        <description>Percentage of participants who die for any reason other than recurrence of disease.</description>
        <time_frame>Cumulative incidence for the entire study, up to 11 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mini-haplo BMT</title>
            <description>Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant-related Mortality</title>
          <description>Percentage of participants who die for any reason other than recurrence of disease.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relapse Rate</title>
        <description>Percentage of participants who experience disease relapse.</description>
        <time_frame>Cumulative incidence for the entire study, up to 11 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mini-haplo BMT</title>
            <description>Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Rate</title>
          <description>Percentage of participants who experience disease relapse.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Percentage of participants who do not experience disease relapse, disease progression, or death.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mini-haplo BMT</title>
            <description>Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Percentage of participants who do not experience disease relapse, disease progression, or death.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Failure Rate</title>
        <description>Percentage of participants who experienced failure to engraft (also called graft failure or graft rejection). Failure to engraft is defined as &lt;5% donor chimerism and absence of relapse or any other reason for that chimerism value. All participants who met this criterion were included in this outcome measure.</description>
        <time_frame>Cumulative incidence for the entire study, up to 11 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mini-haplo BMT</title>
            <description>Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Failure Rate</title>
          <description>Percentage of participants who experienced failure to engraft (also called graft failure or graft rejection). Failure to engraft is defined as &lt;5% donor chimerism and absence of relapse or any other reason for that chimerism value. All participants who met this criterion were included in this outcome measure.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematologic and Non-hematologic Toxicities as Measured by NCI Common Toxicity Criteria for Adverse Events, v 3.0 Weekly Until 1 Year After Transplantation</title>
        <description>Percentage of study participants who experienced a serious adverse event (SAE) within 1 year of bone marrow transplant. Complete data is provided in the Adverse Event tables.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mini-haplo BMT</title>
            <description>Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematologic and Non-hematologic Toxicities as Measured by NCI Common Toxicity Criteria for Adverse Events, v 3.0 Weekly Until 1 Year After Transplantation</title>
          <description>Percentage of study participants who experienced a serious adverse event (SAE) within 1 year of bone marrow transplant. Complete data is provided in the Adverse Event tables.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mini-haplo BMT</title>
          <description>Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Idiopathic pneumonia syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pulmonary Vascular Obstructive Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ephraim Fuchs</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-419-6479</phone>
      <email>fuchsep@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

